Analysts await Kite Pharma, Inc. (NASDAQ:KITE) to report earnings on May, 09 for the fiscal quarter ending Mar 2016.

They expect $-1.22 EPS, down 70.49% or $0.86 from last year’s $-0.36 per share.

At the moment 12 analysts are watching Kite Pharma, Inc. (NASDAQ:KITE), 6 rate it “Buy”, 6 “Outperform”, 0 “Underperform”, 0 “Sell”, while 0 “Hold”.

Looking forward, for the quarter ending Jun-16, 11 analysts have a mean sales target of 4.83 million. For the quarter ending Sep-16, 11 analysts have a mean sales target of 4.99 million whilst for the year ending Dec-16, 12 analysts have a mean target of 19.09 million.

In terms of earnings per share, 11 analysts have a -1.27 EPS mean target for the quarter ending Jun-16, for the quarter ending Sep-16, 11 analysts have a -1.53 EPS mean target and for the quarter ending Sep-16 there are 13 estimates of -5.48 EPS.

The biggest institutional shareholders in Kite Pharma, Inc. include Capital Research Global Investors which owns 6 million shares in the company valued at $366.00 million. Fidelity Management and Research Company is the second biggest holder with 4 million shares currently valued at 218.44 million whilst Vanguard Group Inc has 3 million shares valued at 162.02 million.

Total shares held by institutions as of the most recent company filings are 37,978,815 with a reported 4,019,649 bought and 2,901,657 sold. These holdings make up 77.9% of the company’s outstanding shares.

Currently insiders hold 691,221 shares in the business which makes up 1.42% of shares. The biggest holder currently is Mr. Joshua A. Kazam who owns 215,000 shares (0.44% of those outstanding), whilst Mr. Roy Doumani holds 139,067 (0.28% of shares outstanding) and Cynthia M. Butitta holds 95,401 (0.20% of shares outstanding).

The stock increased 1.96% or $0.86 during the last trading session, hitting $46.88. Kite Pharma, Inc. (NASDAQ:KITE) has fallen 65.29% over the past 6 months and is downtrending.